• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sabra Health Care REIT Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    2/19/25 4:05:47 PM ET
    $SBRA
    Real Estate Investment Trusts
    Real Estate
    Get the next $SBRA alert in real time by email
    sbra-20250219
    false000149229800014922982025-02-192025-02-19

      
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): February 19, 2025
    SABRA HEALTH CARE REIT, INC.
    (Exact name of registrant as specified in its charter)
     
    Maryland 001-34950 27-2560479
    (State of
    Incorporation)
     (Commission
    File Number)
     (I.R.S. Employer
    Identification No.)
     
    1781 Flight Way
    Tustin
    CA
    92782
    (Address of principal executive offices)(Zip Code)
    Registrant's telephone number including area code: (888) 393-8248  
    (Former name or former address, if changed since last report.)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading symbol(s)Name of each exchange on which registered
    Common stock, $0.01 par valueSBRAThe Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02Results of Operations and Financial Condition.
    On February 19, 2025, Sabra Health Care REIT, Inc. (“Sabra”) issued a press release reporting its results of operations for the three month period ended December 31, 2024. The press release refers to the Reconciliations of Non-GAAP Financial Measures that is available on the Investors section of Sabra’s website, free of charge, at www.sabrahealth.com. The text of the press release and the Reconciliations of Non-GAAP Financial Measures are furnished herewith as Exhibits 99.1 and 99.3, respectively, and are specifically incorporated by reference herein.
    Item 7.01Regulation FD Disclosure.
    The press release furnished herewith as Exhibit 99.1 refers to a supplemental information package that is available on the Investors section of Sabra’s website, free of charge, at www.sabrahealth.com. The text of the supplemental information package is furnished herewith as Exhibit 99.2 and is specifically incorporated by reference herein.
    Sabra intends to present the materials attached to this report as Exhibit 99.4 in investor presentations. The furnishing of these materials is not intended to constitute a representation that such furnishing is required by Regulation FD or other securities laws, or that the presentation materials include material investor information that is not otherwise publicly available. In addition, Sabra does not assume any obligation to update such information in the future.
    The information in Items 2.02 and 7.01 of this Form 8-K and the information in Exhibits 99.1, 99.2, 99.3 and 99.4 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference into any filing of Sabra under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in any such filing.
    Item 9.01Financial Statements and Exhibits.
     
    (d)Exhibits.
    99.1
    Press Release of Sabra Health Care REIT, Inc., dated February 19, 2025.
    99.2
    Sabra Health Care REIT, Inc. Supplemental Information Package, dated December 31, 2024.
    99.3
    Reconciliations of Non-GAAP Financial Measures, dated December 31, 2024.
    99.4
    Investor Presentation.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document).





    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    SABRA HEALTH CARE REIT, INC.
    Date: February 19, 2025/S/    MICHAEL COSTA
    Name: Michael Costa
    Title: Chief Financial Officer, Secretary and Executive Vice President




    Get the next $SBRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBRA

    DatePrice TargetRatingAnalyst
    1/17/2025Buy → Hold
    Truist
    1/7/2025$20.00Mkt Perform → Mkt Outperform
    JMP Securities
    12/5/2024$20.00Outperform → Neutral
    Mizuho
    10/1/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    9/13/2024$17.00 → $20.00Neutral → Buy
    Citigroup
    1/30/2024$21.00Buy
    Deutsche Bank
    10/17/2023$16.00Outperform → Market Perform
    BMO Capital Markets
    10/16/2023$13.00 → $15.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings